Jian Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jian Jin has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Banrida Wahlang
Hepatobiology and Toxicology Center, University of Louisville, Louisville, KY 40202, USA
1 shared publication Bo-Li Wang
Department of Burn Surgery, Changhai Hospital, The Naval University, Shanghai, China
1 shared publicationGuo-Sheng Wu
Department of Burn Surgery, Changhai Hospital, The Naval University, Shanghai, China
1 shared publication- Guosheng Wu
Department of Burn Surgery, The First Affiliated Hospital of Naval Medical University , Shanghai 200433
1 shared publication - Josiah E. Hardesty
Division of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Louisville, Louisville, KY 40202, USA
1 shared publication - Kimberly Z. Head
University of Louisville Hepatobiology and Toxicology Center, USA
1 shared publication
Latest Publications
- Open Access
- 21 October 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (12) , 3806-3819
Proteomics and metabolic phenotyping define principal roles for the aryl hydrocarbon receptor in mouse liver
- 21 October 2021
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (12) , 3806-3819
Open AccessProteomics and metabolic phenotyping define principal roles for the aryl hydrocarbon receptor in mouse liver
- Open Access
- 28 May 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Association of Preadmission Statin Use and Mortality in Critically Ill Patients: A Meta-Analysis of Cohort Studies
Background: A large number of studies have been conducted to determine whether there is an association between preadmission statin use and improvement in outcomes following critical illness, but the conclusions are quite inconsistent. Therefore, this meta-analysis aims to include the present relevant PSM researches to examine the association of preadmission use of statins with the mortality of critically ill patients.Methods: The PubMed, Web of Science, Embase electronic databases, and printed resources were searched for English articles published before March 6, 2020 on the association between preadmission statin use and mortality in critically ill patients. The included articles were analyzed in RevMan 5.3. The Newcastle-Ottawa Scale (NOS) was used to conduct quality evaluation, and random/fixed effects modeling was used to calculate the pooled ORs and 95% CIs. We also conducted subgroup analysis by outcome indicators (30-, 90-day, hospital mortality).Results: All six PSM observational studies were assessed as having a low risk of bias according to the NOS. For primary outcome—overall mortality, the pooled OR (preadmission statins use vs. no use) across the six included studies was 0.86 (95% CI, 0.76–0.97; P = 0.02). For secondary outcome—use of mechanical ventilation, the pooled OR was 0.94 (95% CI, 0.91–0.97; P = 0.0005). The corresponding pooled ORs were 0.67 (95% CI, 0.43–1.05; P = 0.08), 0.91 (95% CI, 0.83–1.01; P = 0.07), and 0.86 (95% CI, 0.83–0.89; P < 0.00001) for 30-, 90-day, and hospital mortality, respectively.Conclusions: Preadmission statin use is associated with beneficial outcomes in critical ill patients, indicating a lower short-term mortality, less use of mechanical ventilation, and an improvement in hospital survival. Further high-quality original studies or more scientific methods are needed to draw a definitive conclusion.
- 28 May 2021
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Open AccessAssociation of Preadmission Statin Use and Mortality in Critically Ill Patients: A Meta-Analysis of Cohort Studies
Background: A large number of studies have been conducted to determine whether there is an association between preadmission statin use and improvement in outcomes following critical illness, but the conclusions are quite inconsistent. Therefore, this meta-analysis aims to include the present relevant PSM researches to examine the association of preadmission use of statins with the mortality of critically ill patients.Methods: The PubMed, Web of Science, Embase electronic databases, and printed resources were searched for English articles published before March 6, 2020 on the association between preadmission statin use and mortality in critically ill patients. The included articles were analyzed in RevMan 5.3. The Newcastle-Ottawa Scale (NOS) was used to conduct quality evaluation, and random/fixed effects modeling was used to calculate the pooled ORs and 95% CIs. We also conducted subgroup analysis by outcome indicators (30-, 90-day, hospital mortality).Results: All six PSM observational studies were assessed as having a low risk of bias according to the NOS. For primary outcome—overall mortality, the pooled OR (preadmission statins use vs. no use) across the six included studies was 0.86 (95% CI, 0.76–0.97; P = 0.02). For secondary outcome—use of mechanical ventilation, the pooled OR was 0.94 (95% CI, 0.91–0.97; P = 0.0005). The corresponding pooled ORs were 0.67 (95% CI, 0.43–1.05; P = 0.08), 0.91 (95% CI, 0.83–1.01; P = 0.07), and 0.86 (95% CI, 0.83–0.89; P < 0.00001) for 30-, 90-day, and hospital mortality, respectively.Conclusions: Preadmission statin use is associated with beneficial outcomes in critical ill patients, indicating a lower short-term mortality, less use of mechanical ventilation, and an improvement in hospital survival. Further high-quality original studies or more scientific methods are needed to draw a definitive conclusion.